

CURRICULUM VITAE

William Frank Maragos, M.D., Ph.D.

Born: February 2, 1957
New London, Connecticut

Address: University of Kentucky Medical Center
Dept. of Neurology
Kentucky Clinic, Room L-445
Lexington, KY 40536-0284

Work Phone: 859-323-2522

EDUCATION

- 1971-75 Walt Whitman High School, Bethesda, Maryland
- 1975-79 University of New Hampshire, Durham, New Hampshire; B.S. (Cum laude in Biochemistry)
- 1980-83 University of Michigan, Neuroscience Program, Ann Arbor, Michigan; M.S.
- 1983-85 Tulane University Medical School, New Orleans, Louisiana
- 1985-87 University of Michigan, Neuroscience Program, Ann Arbor, Michigan; Ph.D.
- 1987-88 Northwestern University School of Medicine, Chicago, Illinois; M.D.

POSTDOCTORAL TRAINING

- 1988-89 St. Joseph Mercy Hospital, Ann Arbor, Michigan, Categorical Medical Internship
- 1989-1992 University of Michigan, Ann Arbor, Michigan, Neurology Residency Training
- 1992-1995 Postdoctoral Research (Mentor - Faye S. Silverstein, M.D.)

ACADEMIC APPOINTMENTS

- 7/92-8/95 Lecturer, Department of Neurology, University of Michigan, Ann Arbor, Michigan
- 9/95-6/01 Assistant Professor, Department of Neurology and Dept. of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
- 7/01-present Associate Professor, Departments of Neurology and Anatomy and Neurobiology and Graduate Center for Toxicology, University of Kentucky.

GRANT SUPPORT

Currently Funded

- 2005-2009 American Heart Association. "Targeted Mitochondrial Uncoupling in Focal Cerebral Ischemia". \$400,000 (Bugher Foundation Award - WF Maragos – PI, 20%)
- 2007-2011 Department of Veterans Affairs. "Targeting the Mitochondrial Permeability Transition in Cerebral Ischemia", \$500,000 (VA Merit Award - WF Maragos – Co-I, 20%)

Pending

- 2009-2013 NIDA, NIH. "HIV-1 Protein Tat and Methamphetamine Interactions", \$1,250,000 (R01 - WF Maragos, 35%)
- 2009-2014 NINDS, NIH. "Pharmacology and Function of Mitochondrial NMDA Receptors", \$1,250,000 (R01 - WF Maragos, 35%)

Past

- 1995-1998 University of Kentucky, Physician Scientist Award. "The Role of Antioxidant Pathways in Excitotoxicity" \$150,000 (WF Maragos, PI)
- 1997-2002 NINDS, NIH. "NMDA receptors and DA in a model of oxidative injury" \$414,180. (K08 - WF Maragos, PI)
- 1997-1998 Alzheimer's Disease Research Center, NIH. "Excitotoxicity and oxidative stress in Mn-SOD transgenic mice" \$20,000. (WF Maragos, PI)
- 1997-1998 Medical Center Research, University of Kentucky. "Nitric oxide toxicity in Mn-SOD transgenic mice" \$10,000. (WF Maragos, PI)
- 1999-2004 NINDS, NIH. "Role of glial cell activation in HIV protein induced neurotoxicity" \$686,152 (R01 - WF Maragos, Co-I)
- 2001-2006 NINDS, NIH. "Dopamine toxicity in models of Huntington's disease" \$925,000 (R01 - WF Maragos, PI)
- 2001-2006 NIA, NIH. "The mechanisms of manganese superoxide dismutase-mediated neuroprotection". \$676,903 (P01 – WF Maragos, Co-I, D.K. St. Clair, Project Leader, Project #3, W. Markesbery, P.I.)
- 2000-2005(7) NIDA, NIH. "Methamphetamine and HIV protein-induced neurotoxicity" \$900,000 (R01 - WF Maragos)

CERTIFICATION AND LICENSURE

Kentucky State License
American Board of Psychiatry and Neurology

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

American Academy of Neurology
American Association for the Advancement of Science
American Neurological Association
Society for Neuroscience
Medical Advisor – Huntington's Disease Society of America – Kentucky Chapter

Huntington's Study Group

COMMITTEES

1997 - 2001	College of Medicine MD/PhD Admissions Committee, UKMC
1997 - 2001	College of Medicine Graduate Studies Committee, UKMC
1998 - 2001	Assoc. Director, Neurology Residency Training Program
1998	Department of Physiology Faculty Search Committee, UKMC
1999	Search Committee, Director of the Spinal Cord and Brain Injury Research Center, UKMC
2000 - 2003	University of Kentucky College of Medicine Research Committee
2001 - 2005	Physician Scientist Committee
2002-	University of Kentucky Medical Center Research Advisory Committee
2002 - 2005	General Clinical Research Center Protocol Review Subcommittee
2002- 2003	Dept. Anatomy and Neurobiology Faculty Search Committee
2004-	Advisory Committee, Building Interdisciplinary Research Careers in Women's Health grant
2006-present	University of Kentucky Medical Center Faculty Council

EDITORIAL/GRANT REVIEW EXPERIENCE

Ad Hoc Reviewer :

Annals of Neurology
BMC Neuroscience
Brain Research
Brain Research Bulletin
Cellular and Molecular Life Sciences
European Journal of Neuroscience
Experimental Neurology
Free Radical Biology & Medicine
Journal of Acquired Immune Deficiency Syndromes
Journal of Neurochemistry
Journal of Neuroscience
Journal of Neuroscience Methods
Journal of Neurovirology
Neurology
Neuropharmacology
Neurotoxicology Research
Pharmacology, Biochemistry and Behavior
Proceedings of the National Academy of Sciences

2003 Ad Hoc NIH Grant Reviewer – ZNS1 SRB-H

2007 American Federation of AIDS Research

2007 Israel Science Foundation

CLINICAL ACTIVITIES

1992-1995 Neurology Ward and Consult Attending, Veterans Administration Medical Center, Ann Arbor, Michigan

General Neurology Clinic, Veterans Administration Medical Center, Ann Arbor, Michigan

Movement Disorders Clinic, University of Michigan Medical Center

9/95 -present Attending Neurologist and Co-Director Movement Disorders Clinic,
University of Kentucky Medical Center

INVITED LECTURES/PRESENTATIONS

- | | |
|-----------------|--|
| December, 1998 | Does Dopamine Contribute to Striatal Damage in Huntington's Disease? Sanders Brown Center on Aging, Lexington, KY |
| March, 1999 | Does Dopamine Contribute to Striatal Damage Caused by Impaired Mitochondrial Function? New York Academy of Sciences, NY |
| October, 2000 | Dopamine toxicity in a model of Huntington's Disease - Dept. Toxicology, University of Kentucky, Lexington, KY |
| November, 2001 | Mitochondria, Excitotoxicity and Neurodegeneration
Bristol Myers Squibb, Wallingford, CT |
| June, 2002 | Synergistic Neurotoxicity of Methamphetamine and HIV-Tat Protein
University of San Diego and Scripps Institute, La Jolla, CA |
| March, 2002 | Mitochondrial Uncoupling as Therapy in Excitotoxic Neurodegeneration? Sanders Brown Center on Aging, Lexington, KY |
| June 2005 | NIM811 Prevents Induction of Mitochondrial Permeability in Cerebral Ischemia, International Society for Cerebral Blood Flow and Metabolism, Amsterdam, Netherlands |
| August, 2005 | Human Immunodeficiency Virus-1 Protein Tat and Methamphetamine Interactions, International Society for Neurochemistry/European Society for Neurochemistry, Isola di San Servolo, Venice, Italy |
| September, 2005 | Targeting Mitochondrial Uncoupling in Cerebral Ischemia, Molecular and Cellular Basis of Aging Symposium, University of Kentucky, Lexington, KY |
| December, 2005 | Methamphetamine- and HIV-1 Tat-Induced Mitochondrial Dysfunction, Neurobiology of HIV, Psychiatric and Substance Abuse Co-morbidity Conference, National Institute of Drug Abuse, Bethesda, MD. |
| March, 2006 | Human Immunodeficiency Virus-1 Protein Tat and Methamphetamine Interactions, NeuroAIDS, Drug Abuse and Inflammation: Building a Collaborative Research Agenda, National Institute of Drug Abuse, Bethesda, MD. |
| March, 2006 | Targeting Cyclophilins in Acute CNS Injury: Cerebral Ischemia, Cyclophilin Modulation Biology Workshop, Novartis Institutes for BioMedical Research Inc., Cambridge, MA. |

April, 2006

Huntington's Disease: Need for New Therapies, Lexington
Conference on RNA Therapy for Neurodegenerative Diseases,
University of Kentucky, Lexington, KY.

BIBLIOGRAPHY

Peer Reviewed Publications

1. Maragos WF, Chu DCM, Greenamyre JT, Penney JB and Young AB. High correlation between the localization of [³H]TCP binding and NMDA receptors. Eur J Pharmacol 123:173-174, 1986.
2. Maragos WF, Greenamyre JT, Penney JB and Young AB. Glutamate dysfunction in Alzheimer's disease: An hypothesis. Trends Neurosci 10:65-67, 1987.
3. Maragos WF, Chu DCM, Young AB, D'Amato CJ and Penney JB Jr. Loss of hippocampal [³H]TCP binding in Alzheimer's disease. Neurosci Lett 74:371-376, 1987.
4. Maragos WF, Penney JB and Young AB. Anatomical correlation of NMDA and TCP receptors in rat brain. J Neurosci 8:493-501, 1988.
5. Greenamyre JT, Maragos WF, Albin WF, Penney JB and Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuro-Psychopharmacol & Biol Psychiat 12:421-430, 1988.
6. Maragos WF, Newman SW, Lehman MN and Powers JB. Neurons of origin and fiber trajectory of amygdalofugal projections to the medial preoptic area in Syrian hamsters. J Comp Neurol 280:59-71, 1989.
7. McDonald JW, Cline HT, Constantine-Paton M, Maragos WF, Johnston MV and Young AB. Quantitative autoradiographic localization of NMDA, quisqualate and PCP receptors in the frog tectum. Brain Res 482:155-158, 1989.
8. Penney JB, Maragos WF, Greenamyre JT, Debowey DL, Hollingsworth Z and Young AB. Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. J Neurol Neurosurg and Neuropsych 53:314-320, 1990.
9. Maragos WF, Greenamyre JT, Chu DCM, Penney JB and Young AB. A study of cortical and hippocampal NMDA and PCP receptors following selective cortical and subcortical lesions. Brain Res 538:36-45, 1991.
10. Greenamyre JT and Maragos WF. Neurotransmitter receptors in Alzheimer's Disease. Cerebrovasc Brain Metab Reviews 5:61-94, 1993.
11. Maragos WF and Silverstein FS. The neonatal rat brain is resistant to the toxic effects of the NO generator nitroprusside. Neurosci Lett 172:80-84, 1994.
12. Koller WC, et al., The relationship of essential tremor to other movement disorders- report on 678 patients. Ann Neurol 35: 717-723, 1995.
13. Maragos WF and Silverstein FS: Inhibition of nitric oxide synthase attenuates striatal lesions produced by malonate in rat. J Neurochem 64:2362-2365, 1995.
14. Maragos WF and Silverstein FS: The mitochondrial inhibitor malonate enhances NMDA toxicity in the neonatal rat striatum. Develop Brain Res 88:117-121, 1995.

15. Maragos WF, Jakel RJ, Pang Z and Geddes JW. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp Neurol 154:637-644, 1998.
16. Kruman II, Nath A, Maragos WF, Chan SL, Jones M, Rangnekar VM, Jakel RJ and Mattson MP. Evidence that Par-4 participates in the pathogenesis of AIDS dementia. Am J Pathol 155:39-46, 1999.
17. Nath A, Booze RM, Hauser K, Mactutus C, Bell J, Cass W, Maragos W and Berger J. Interactions of Drugs of Abuse and HIV dementia. NeuroAIDS 2, 1999.
18. Maragos WF, Chesnut MD and Jakel RJ: Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168-172, 1999.
19. Maragos WF, Jakel RJ, Chesnut MD, Geddes JW and Dwoskin LP. Does dopamine contribute to striatal damage caused by impaired mitochondrial function? Ann NY Acad Sci 893: 345-349, 1999.
20. Nath A, Booze RM., Hauser KF, Mactutus C, Bell JE, Cass WA, Maragos WF, Berger JR. Critical Questions for Neuroscientists in Interactions of Drugs of Abuse and HIV infection. NeuroAIDS 2 Vol. 2, Issue 11 (www.Sciencemag.org)1999.
21. Jakel RJ and Maragos WF. Huntington's disease neuronal cell death: a potential role for dopamine. Trends Neurosci 23: 239-245, 2000.
22. Keller JN, Huang FF, Dimayuga ER and Maragos WF. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Rad Biol Med 29: 1037-1042, 2000.
23. Maragos WF, Jakel R, Chesnut D, Pocernich CB, Butterfield DA, St. Clair DK, and Cass WA. Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase, Brain Res 878:218-222, 2000.
24. Bansal AK, Mactutus CF, Nath A, Maragos WF, Hauser KF and Booze RM. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 879:42-49, 2000.
25. Nath A, Jones M, Maragos WF, Booze R, Mactutus C, Bell J and Mattson MP. Neurotoxicology and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharm 14: 222-228, 2000.
26. Turchan JT, Anderson C, Hauser K, Sun Q, Zhang J, Liu Y, Wise PP, Kruman I, Mattson MP, Booze R and Nath A. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neuroscience 2: 3, 2001.
27. Nath A, Maragos WF, Avison M, Schmitt F and Berger JR. Acceleration of HIV dementia with methamphetamine and cocaine use. J Neurovirol 7:66-71, 2001.
28. Berger JR, Dobbs MR, Terhune MH and Maragos WF. The neurologic complications of scleromyxedema. Medicine 80:313-9, 2001
29. Maragos WF, Jun Zhu, Chesnut MD and Dwoskin LP. Mitochondrial toxins inhibit [³H]Dopamine uptake in rat striatal synaptosomes. Biochem Pharm 7201:1-7, 2002.

30. Flora G, Lee YW, Nath A, Maragos W, Henning B and Toborek M. Methamphetamine-induced TNF- α gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. NeuroMolecular Medicine 2:71-85, 2002.
31. Maragos WF, Young KL, Altman CA, Turchan JT, Pauly, JR, Guseva M, Nath A and Cass WA. HIV-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83:955-963, 2002.
32. Nath A, Hauser KF, Wojna V, Booze RM, Maragos WF, Prendergast M, Cass W and Turchan JT. Molecular basis for interaction of HIV and drugs of abuse. J Acquir Immune Defic Syndr Oct 1;31 Suppl 2:S62-9, 2002.
33. Flora G, Lee WF, Nath A, Henning B, Maragos W and Toborek. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol 179: 60-70, 2003.
34. Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE and Nath A. Neuronal injury in CA3 Region and dentate gyrus of hippocampus with HIV-1 Tat protein. Neuroscience 117:43-53, 2003.
35. Maragos WF, Young KL, Dean JL, Rockich KT. Pre- or post-treatment with the mitochondrial uncoupler 2,4-dinitrophenol attenuates striatal quinolinate lesions. Brain Res 966:312-316, 2003.
36. Cass WA, Harned ME, Peters LE, Nath A and Maragos WF. Potentiation of the dopamine-depleting effects of neurotoxic doses of methamphetamine in the rat by HIV-1 protein Tat. Brain Res 984:133-142, 2003.
37. Hauser, K.F., W.F. Maragos, M. Toborek, W.A. Cass, J. Turchan, C. Pardo, K. Conant, R.M. Booze, C.F. Mactutus, V.K. Khurdayan, P.M. Heron, I.N. Singh, and A. Nath, Synergistic disruption of neural function by drug abuse and human immunodeficiency virus-1. Natl. Institute on Drug Abuse Proceedings, USPHS, Proceedings of the NIDA-Sponsored Satellite Sessions in Association with the XIV International AIDS Conference, Barcelona, Spain, July 7-11, 2003.
38. Jin Y, McEwen M, Nottingham SA, Maragos WF, Gragicovic NB, Sullivan PG and Springer JE. The mitochondrial uncoupling agent 2,4-dinitrophenol improves mitochondrial function, attenuates oxidative damage and increases white matter sparing in the contused spinal cord. J Neurotrauma 21: 1396-1404. 2004.
39. Maragos WF and Korde AS. Mitochondrial uncoupling as a potential therapeutic target in acute central nervous system injury. J Neurochem 91:257-262, 2004.
40. Maragos WF, Young KL, Altman CA, Pocernich CB, Drake J, Butterfield DA, Seif I, Holschneider DP, Chen K and Shih JC. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res 29:741-746, 2004.
41. Korde AS, Pettigrew LC, Craddock SD and William F. Maragos WF. The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. J Neurochem 94:1676-1684, 2005.

42. Korde AS, Sullivan PG and Maragos WF. The uncoupling agent 2,4-dinitrophenol improves mitochondrial homeostasis following striatal quinolinic acid injections. J. Neurotrauma 22, 1142-1149, 2005.
43. Smith RR, Dimayuga ER, Keller JN and Maragos WF. Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y Cells. Neurochem Res 30:527-31, 2005.
44. Perluigi M, Poon HF, Maragos WF, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C and Butterfield DA. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice - A model of Huntington's Disease. Molecular and Cellular Proteomics 4:1849-61, 2005.
45. Theodore S, Cass WA and Maragos WF. Methamphetamine and Human Immunodeficiency Virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137: 925-935, 2006.
46. Theodore S, Cass WA and Maragos WF. Involvement of cytokines in Human Immunodeficiency Virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol 199:490-498, 2006.
47. Theodore S, Nath A, Young K, Cass WA and Maragos WF. Inhibition of tumor necrosis factor- α signaling prevents Human Immunodeficiency Virus-1 protein Tat and methamphetamine interactions. Neurobiol Dis 23: 663-668, 2006.
48. Theodore S, Stolberg S, Cass WA and Maragos WF. Human Immunodeficiency Virus-1 protein Tat and methamphetamine interactions. Ann NY Acad Sci 1074: 178-190, 2006.
49. Berman J, Carson M, Chang L, Cox B, Fox H, Gilberto-Gonzalez R, Hanson G, Hauser K, Ho W, Hong JS, Majo E, Mandler R, Maragos W, Masliah E, McArthur J, Miller D, Nath A, O'Callaghan J, Persidsky Y, Power C, Rogers T, Royal W and Shortlift D. NeuroAIDS, Drug Abuse, and Inflammation: Building a Collaborative Research Agenda. J Neuroimmune Pharmacol. 1:351-99, 2006.
50. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y, Volsky DJ and Knapp PE. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 100: 567-586, 2007.
51. Korde AS, Pettigrew LC, Craddock SD, Waldmeier PC and Maragos WF. Protective effects of NIM811 in transient focal cerebral ischemia suggest involvement of the mitochondrial permeability transition. J Neurotrauma 24:895-908, 2007.
52. Theodore S, Cass WA, Nath A. and Maragos WF. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Current HIV Research 5: 301-313, 2007.
53. Pandya JD, Pauly JR, Nukala VN, Sebastian AH, Day KM, Korde AS, Maragos WF, Hall ED and Sullivan PG. Mitochondrial uncouplers as possible therapeutic interventions following traumatic brain injury. J Neurotrauma 24:798-811, 2007.
54. Korde, AS, Pocerlich CB and Maragos WF. Effects of the uncoupling agent DNP on mitochondrial membrane potential and bioenergetics. Submitted.

Chapters in Books

1. Penney JB, Maragos WF, Chu DCM, Young AB. Quantitative autoradiography of [³H]TCP binding to Alzheimer's disease hippocampus. In: Excitatory Amino Acid Transmission, Alan R. Liss, Inc., New York, 1987, pp 127-30.
2. Young AB, Greenamyre JT, Maragos WF, Penney JB. Glutamate receptors in Alzheimer's disease. In: Excitatory Amino Acid Transmission, Alan R. Liss, Inc., New York, 1987, pp 233-240.
3. Maragos WF, Chu DCM, Young AB, Penney JB. Effects of selective cortical and subcortical lesions on TCP and NMDA receptor binding. In: Sigma Opioid Phencyclidine-like Compounds as Molecular Probes in Biology, Neuropsychopharmacology Books, Ann Arbor, 1988, pp 309-314.
4. Young AB, Maragos WF, Penney JB. Regional localization of NMDA and TCP binding in mammalian brain. In: Sigma Opioid Phencyclidine-like Compounds as Molecular Probes in Biology, Neuropsychopharmacology Books, Ann Arbor, 1988, pp 269-276.
5. Chu DCM, Maragos WF, Penney JB, Young AB. Magnesium ions increase binding affinity of dissociative anesthetic receptors but not of NMDA receptors in rat brain. In: EA Caralheiro, J Lehmann, L Turski (eds), Frontier in Excitatory Amino Acid Research, Neurology and Neurobiology, Alan R. Liss, Inc., New York, 1988 (46), pp 567-570.
6. Young AB, Cha JJ, Greenamyre JT, Maragos WF, Penney JB. Distribution of PCP and glutamate receptors in normal and pathologic mammalian brain. In: E Costa and E Barnard (eds), The Allosteric Modulation of Amino Acid Receptors and its Therapeutic Implications, Raven Press, 1989, pp 357-375.

Doctoral Dissertation

[³H]TCP as a potential anatomical marker for N-methyl-D-aspartate receptors.

Abstracts

1. Maragos WF, Lehman MN, Winans SS. Vomeronasal amygdaloid input to the medial preoptic "mating center" of the male Golden hamster. Soc Neurosci Abstr 8:872, 1982.
2. Young AB, Maragos WF, Greenamyre JT, Penney JB. Studies of cortical glutamate receptors in nucleus basalis lesioned rats. Soc Neurosci Abstr 12:343, 1986.
3. Maragos WF, Debowey DL, Reiner A, Rustioni A, Penney JB, Young AB. Co-localization of Congo Red-stained neurofibrillary tangles in glutamate immunoreactive neurons in the hippocampus. Soc Neurosci Abstr 12:442, 1986.
4. Penney JB, Maragos WF, Chu DCM, Young AB. Correlation between localization of [³H]TCP and NMDA binding sites. Soc Neurosci Abstr 12:385, 1986.
5. Maragos WF, Penney JB, Young AB. Hippocampal neuronal localization of NMDA and TCP receptors. Soc Neurosci Abstr 13:760, 1987.

6. Debowey DL, Maragos WF, Hollingsworth Z, Greenamyre JT, Young AB, Penney JB. Receptor changes in hippocampus of Alzheimer's disease. Soc Neurosci Abstr 13:439, 1987.
7. Young AB, Albin RL, Penney JB, Greenamyre JT, Maragos WF. 1,2,3,4-tetrahydro-9-aminoacridine and other acridine derivatives are displacers of specifically bound [³H]-N-(1-[2-thienyl]cyclohexyl)-3,4-piperidine. Soc Neurosci Abstr 13:1553, 1987.
8. Chu DCM, Maragos WF, Penney JB, Young AB. Magnesium ions increase binding affinity of dissociative anesthetic receptors but not of NMDA receptors in rat brain. Neurochem Int 12 (Suppl 1):36, 1988.
9. Maragos WF, Albin RL, Sakurai SY, Makowicz RL, Higgins DS, Young AB, Penney JB. Excitatory and inhibitory amino acid receptors in human striate cortex. Soc Neurosci Abstr 16:1191, 1990.
10. Maragos WF, Newman SW, Penney JB, Young AB. Excitatory amino acid receptors in control and Alzheimer's amygdala. Soc Neurosci Abstr, 17:795, 1991.
11. Maragos WF. Inhibition of nitric oxide synthase attenuates striatal lesions produced by malonate in rat. Neuropharmacology: Nitric oxide in the Nervous System, 1994.
12. Maragos WF, Fox RS, Ben-Yoseph O and Ross B. Excitotoxic striatal lesions induced by the antioxidant enzyme inhibitor mercaptosuccinate. Soc Neurosci Abstr 22: 223, 1996.
13. Maragos WF, Fox RA, Bruce AD, Mattson MP, Yen H-C and St. Clair DK. Kainic acid-induced neuronal loss in the hippocampus is regionally attenuated in transgenic mice that overexpress manganese superoxide dismutase (Mn-SOD). Soc Neurosci Abs 23: 2295, 1997
14. Maragos WF, Tillman P, Jones M and Nath A. Pattern of hippocampal injury with HIV-1 Tat protein. Neurosci HIV Infection, 1998.
15. Maragos WF, Jakel RJ, Chesnut MD, Geddes JW and Dwoskin LP. Does dopamine contribute to striatal damage caused by impaired mitochondrial function? N. Y. Acad. Sci. 1999.
16. Nath A, Maragos W, Booze R, Mactutus C, Anderson C, Jones M and Bell J. Enhancement of HIV protein induced neurotoxicity with methamphetamine and cocaine. American Neurological Association, 1999.
17. Nath A, Booze RM, Hauser K, Maragos W, Cass W and Mactutus C. Dopaminergic and non-dopaminergic interactions between HIV proteins and drugs of abuse. NIDA workshop on Metabolic disorders in the pathogenesis of nervous system damage in HIV infected drug abusers. Rockville, MD, 1999.
18. Maragos WF, Nath A and Cass WA. Striatal dopamine loss following injections of gp120/Tat. Neuroscience of HIV Infection 2000.
19. Turchan JT, Anderson C, Hauser KF, Liu Y, Booze RM, Maragos W, Wise P and Nath A. Mechanisms of estrogen protection against HIV proteins, methamphetamine and cocaine neurotoxicity. Soc. Neurosci. 26, 1061, 2000.

20. Rockich KT, Edgar N and Maragos WF. Catecholamine-induced alterations in mitochondrial membrane potential and oxidative stress. Soc. Neurosci. 27, 99.3, 2001.
21. Maragos WF, Nath A and Cass WA. Synergistic toxicity between HIV “Tat” protein and methamphetamine. Soc. Neurosci. 27, 337.7, 2001.
22. Jin Y, Nottingham SA, Young KL, Maragos WF and Springer JE. Pretreatment with the mitochondrial uncoupling agent DNP and functionally recovery after spinal cord injury. National Neurotrauma Society, 2001.
23. Maragos WF, Nath A and Cass WA. Synergistic toxicity between HIV “Tat” protein and methamphetamine. 4th International Symposium on NeuroVirology, Dusseldorf, Germany, June 2002.
24. Cass WA, Harned ME, Peters LE, Nath A and Maragos WF. HIV protein Tat potentiation of the neurotoxic effects of methamphetamine in the rat striatum. 4th International Symposium on NeuroVirology, Dusseldorf, Germany, June 2002.
25. Cass WA, Harned ME, Peters LE, Nath A and Maragos WF. HIV protein Tat potentiation of the neurotoxic effects of methamphetamine in the rat striatum. Dopamine 2002 International Meeting, Portland, OR, July 2002.
26. Korde AS, Sullivan PG and Maragos WF. Treatment with the Mitochondrial Uncoupler 2,4-Dinitrophenol Attenuates Quinolinic Acid-Induced Mitochondrial Dysfunction. Soc. Neurosci. 29, 153.4, 2003.
27. Sullivan PG, Rathmann AM, Thompson BM, Gibson TR, Maragos WF, Korde AS and Hall ED. Mitochondrial uncoupling: a novel therapeutic intervention for traumatic brain injury. Soc. Neurosci. 29: 845.6, 2003.
28. Korde AS, Sullivan PG, Pettigrew LC and Maragos WF. 2,4-Dinitrophenol attenuates quinolinic acid- and ischemic induced mitochondrial dysfunction. Mitochondria and Neuroprotection Symposium, Ft. Lauderdale Florida, 2004.
29. Maragos WF, Korde AS, Waldmeier PC, Craddock, SD and Pettigrew LC. NIM811 prevents induction of mitochondrial permeability in cerebral ischemia. International Society for Cerebral Blood Flow and Metabolism, Amsterdam, Neth. 2005.
30. Maragos WF, Korde AS, Waldmeier PC, Craddock SD and Pettigrew LC. Targeting Mitochondria in Focal Cerebral Ischemia, 130th Annual Meeting of the American Neurological Association, San Diego, CA. 2005.
31. Korde AS, Craddock SD and Pettigrew LC Maragos WF. The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. Soc. Neurosci. 31, 550.13, 2005.32.
32. Theodore S and Maragos WF. Human immunodeficiency virus-1 Tat and methamphetamine interact to enhance cytokine release and oxidative stress in the rat striatum. Soc. Neurosci. 31:907.13, 2005.
33. Maragos WF, Self RL, Theodore S, Deaciuc AG, Dwoskin LP and Cass WA. Human Immunodeficiency Virus-1 Protein Tat Reduces the K⁺-Evoked Release of Striatal Dopamine: Implications for VMAT-2 Function. Accepted, 14th Annual Conference, Society on Neuroimmune Pharmacology, 2008.

